Avecho Advances Phase III CBD Trial for Insomnia Treatment

Avecho Biotechnology Limited (ASX: AVE) has announced that 131 patients have been dosed in its ongoing Phase III clinical trial evaluating its TPM-enhanced oral CBD capsule for insomnia treatment. The trial, following a licensing deal with Sandoz AG earlier this year, gained momentum with the activation of three new recruitment sites in Sydney and the Gold Coast. Recruitment is progressing well across four cities, and the company expects to complete enrolment of the 210 patients needed for interim analysis in the second half of 2025.

Results of the interim analysis are anticipated in early 2026. This trial is one of the largest CBD-focused studies for insomnia and is designed to meet the regulatory standards of the TGA, FDA, and EMA. Avecho’s proprietary TPM technology enhances CBD absorption and may offer a novel treatment for millions suffering from chronic insomnia globally, with significant market potential in the expanding sleep health sector.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com